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Abstract 32 
Asymptomatic and persistent colonisation of the upper respiratory tract by Neisseria 33 
meningitidis occurs despite elicitation of adaptive immune responses against surface 34 
antigens. A putative mechanism for facilitating host persistence of this bacterial 35 
commensal and pathogen is alterations in expression of surface antigens by simple 36 
sequence repeat (SSR)-mediated phase variation. We investigated how often phase 37 
variation occurs during persistent carriage by analysing the SSRs of eight loci in multiple 38 
isolates from 21 carriers representative of 1-6 months carriage. Alterations in repeat 39 
number were detected by a GeneScan analysis and occurred at 0.06 40 
mutations/gene/month of carriage. The expression states were determined by Western 41 
blotting and two genes, fetA and nadA, exhibited trends towards low expression states. A 42 
critical finding from our unique examination of combinatorial expression states, 43 
‘phasotypes’, was for significant reductions in expression of multiple phase-variable 44 
surface proteins during persistent carriage of some strains. The immune responses in 45 
these carriers were examined by measuring variant-specific PorA IgG antibodies, capsular 46 
group Y IgG antibodies and serum bactericidal activity in concomitant serum samples. 47 
Persistent carriage was associated with high levels of specific IgG antibodies and serum 48 
bactericidal activity whilst recent strain acquisition correlated with a significant induction of 49 
antibodies. We conclude that phase variable genes are driven into lower expression states 50 
during long-term persistent meningococcal carriage, in part due to continuous exposure to 51 
antibody-mediated selection, suggesting localised hypermutation has evolved to facilitate 52 
host persistence. 53 
 54 
55 
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INTRODUCTION 56 
Heightened mutation or recombination rates in specific regions of bacterial genomes are a 57 
feature of many bacterial commensals and pathogens (1-4). The mechanisms responsible 58 
for this localised hypermutation are diverse (e.g. site-specific recombination and slippage 59 
in repetitive DNA tracts), but generate high frequencies of variation in a stochastic manner 60 
usually prior to exposure to a selective pressure (5). These hypermutable loci are termed 61 
contingency loci and are speculated to have evolved as a mechanism for adaptation to 62 
rapid, unpredictable and undetectable fluctuations in selective pressures. Localised 63 
hypermutation is therefore likely to contribute to both host adaptation and the disease 64 
phenotypes of bacteria but few studies have examined the frequency and types of events 65 
occurring during natural infections by these organisms (6-9). 66 
Infections by Neisseria meningitidis (Nm) can result in septicaemia and meningitis. 67 
Disease is rapid in onset and has high rates of mortality and morbidity with infants 68 
exhibiting the highest prevalence of disease. Vaccine-elicited serum bactericidal 69 
antibodies (SBA) provide effective protection against Nm infections (10,11). Despite this, 70 
Nm normally exists as a commensal on the naso/oropharyngeal surfaces of humans with 71 
high frequencies of asymptomatic carriage in teenagers and young adults (12). 72 
Meningococci can persist in individual hosts for 6-12 months with carriage eliciting 73 
adaptive immune responses against surface determinants (13). The SBA of carriers 74 
correlates with protection against disease by homologous strains (14,15) but is also 75 
thought to mediate prevention of carriage of homologous strains. Evidence for the latter is 76 
based on observations such as sequential carriage and replacement of one strain by 77 
another strain with antigenically-mismatched outer membrane proteins (16) and herd 78 
protection associated with meningococcal serogroup C (MenC) and serogroup A (MenA) 79 
conjugate vaccination (17, 18). This raises a puzzling feature of meningococcal carriage, 80 
namely, how does this bacterium persist in the face of an adaptive immune response 81 
directed against surface antigens. 82 
Microsatellites or simple sequence repeat (SSR) tracts are a major mechanism of 83 
localised hypermutation being subject to high rates of insertions and deletions of repeats 84 
during DNA replication (3). The reversible nature of SSR mutations has enabled evolution 85 
of phase variation (PV), i.e. high frequency, reversible alterations in phenotypic 86 
expression, for a diversity of surface molecules. In Nm, 40-60 genes per genome are 87 
subject to SSR-mediated PV with these simple sequence contingency loci (SSCL) 88 
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encoding outer membrane proteins, enzymes involved in modulation of the surface 89 
exposed-glycans of lipopolysaccharide and pilin, and restriction-modification systems 90 
(9,19). The SSRs are present either within the reading frame, resulting in ON/OFF 91 
switches in expression, or the promoter, driving modulations of gene expression. The 92 
majority of Nm SSRs are polyC or polyG tracts, but there are also tetra-, penta-, hepta- 93 
and longer repeat units. The outer membrane proteins encoded by Nm SSCLs include a 94 
porin (PorA), iron-acquisition proteins (HmbR, HpuAB, FetA), adhesins and invasins (Opc, 95 
Opa, NadA), and autotransporters (MspA/AusI, NalP/AspA, NadA). These proteins have 96 
important primary functions – such as iron acquisition (e.g. HpuA, HmbR) and adhesion 97 
(e.g. Opc, NadA, MspA) to host tissues - associated with their expression and hence 98 
phase-variants in an ON or high expression state are likely to contribute to survival on 99 
nasopharyngeal surfaces (20,21). Host persistence may be further facilitated by the 100 
secondary functions of some of these proteins, for example, Opc contributes to 101 
complement resistance (22,23). Selection for expression of the phenotypes associated 102 
with these SSCLs is, therefore, potentially strong during host persistence. Conversely, an 103 
opposing ‘counter’ selection for phase variants in an OFF or reduced expression state is 104 
presumed to occur due to adaptive immune responses. The PorA and Opc proteins elicit 105 
bactericidal antibodies during carriage (13,24) and porA phase variants, exhibiting reduced 106 
expression of the PorA protein, can mediate escape of bactericidal antibodies in vitro (25). 107 
PV of meningococcal SSCLs could therefore confer a major advantage as Nm persists on 108 
mucosal surfaces during carriage, however, it is currently unclear whether phase variable 109 
switches actually occur during carriage of Nm in native hosts nor whether there are 110 
particular patterns of switching. 111 
Characterisation of genetic variation during natural infections provides key 112 
indications of how bacterial commensals and pathogens colonise and persist in their hosts. 113 
Localised hypermutation is a phenomenon that is presumed to facilitate bacterial 114 
adaptation to the fluctuating and opposing selective pressures (e.g. adherence versus 115 
immune avoidance) encountered in host environments. In this study we set out to 116 
determine how often SSR-mediated PV occurs in meningococci during natural infections 117 
and to examine whether changes were driven by adaptive immune responses. Our studies 118 
provide the first definitive information on the frequencies of localised hypermutation 119 
occurring during long-term persistence of meningococci on the pharyngeal tissues of their 120 
native hosts. Critically, our unique combinatorial investigation of multiple phase variable 121 
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loci indicates that host persistence is associated with a heightened prevalence of 122 
‘phasotypes’ with lower expression states for multiple surface proteins. A simultaneous 123 
evaluation of the immune responses in these carriers suggests that selection for low 124 
expression ‘phasotypes’ is driven by continuous exposure to immune selective pressures. 125 
 126 
MATERIALS AND METHODS 127 
Bacterial isolate growth and characterisation. All meningococcal isolates were 128 
obtained from a carriage study performed in Nottingham University between November 129 
2008 and May 2009 as described previously (16). The study was approved by the 130 
Nottingham University Medical School Ethics Committee, and written informed consent 131 
was obtained from all volunteers. Up to twenty single colonies were re-streaked from initial 132 
selective plates onto Columbia chocolate agar plates (Oxoid). After overnight growth at 133 
37oC in 5% CO2, sweeps of growth were used for preparation of glycerol stocks in BHI 134 
broth plus 20% glycerol and genomic DNA by extraction with a DNAeasy Blood and Tissue 135 
kit (Qiagen). For expression analyses, strains were initially grown overnight in BHI broth at 136 
37oC and then diluted 10-fold in BHI broth followed by growth for 4-6 hours. Iron-repressed 137 
genes were induced by addition of desferal at a working concentration of 30 μM to a mid-138 
log phase culture followed by incubation for an additional 1-2 hours. 139 
Typing of two isolates per time point was described previously (16). Typing of 140 
additional isolates was performed by PCR amplification with relevant capsule specific PCR 141 
primers and primers specific for the relevant variable regions of the porA and fetA genes 142 
as described previously (see (16) and Table A1). 143 
 144 
Enumeration of SSR repeat numbers. The SSRs of each gene (i.e. fetA, porA, opc, 145 
hpuA, hmbR, nadA, mspA, and nalP) for each strain were amplified and sequenced using 146 
published or newly-designed primers spanning the repeat tract by previously described 147 
methods (16, 25, 26, 27; Table A1). The number of repeats in SSRs of additional isolates 148 
for each strain were determined by a GeneScan protocol as described elsewhere (28, 29). 149 
Briefly, SSRs were amplified using two oligonucleotides, one of which was labelled on the 150 
5’ end with a fluorescent dye (FAM, 6-carboxyfluorescein), and subjected to 151 
electrophoresis on an ABI3730 autosequencer in comparison to a GeneScan500LIZ size 152 
standard (Applied Biosystems). Product sizes were calculated using PeakScanner v1.0 153 
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(Applied Biosystems) and repeat numbers determined by comparison to controls of known 154 
size and repeat number from the same strain and hence presumed to have identical 155 
flanking sequences. A sub-set of tracts were analysed by sequencing to confirm repeat 156 
numbers (see Tables A2 and A3). Mononucleotide repeat tracts of ≥9 units produced two 157 
or more labelled products due to slippage during PCR amplification. The ratio of the areas 158 
of the primary and secondary peaks was determined and if the ratio was above 1.2 the 159 
primary peak was utilised for determining repeat number otherwise the peak with the 160 
largest size was selected. 161 
 162 
Comparative measurements of gene/protein expression levels. A semi-quantitative 163 
measure of protein expression levels for different phase variants of each strain was 164 
performed by probing Western blots of meningococcal whole cell lysates with specific 165 
antibodies (Table 1A). Meningococcal isolates were grown to mid-log phase either in the 166 
presence or absence of an iron chelator in order to induce genes repressed by high iron 167 
levels (i.e. fetA and hpuA). Cells were washed twice before being resuspended in 168 
phosphate buffered saline (PBS). Cell numbers were adjusted to a constant OD550 and 169 
then mixed with 2X SDS loading buffer at a 1:1 ratio. Cell lysates were electrophoresed on 170 
8% polyacrylamide gels and transferred to PVDF membranes by application of fixed 171 
current for 1 hour. Membranes were blocked overnight at 4oC in PBST-Milk (PBS/0.5% 172 
Tween20 plus 5% skimmed milk) and subsequently probed with an appropriate primary 173 
antibody diluted in PBST-Milk for 2 hours. Membranes were then washed three times with 174 
PBST (PBS/0.5% Tween20) and then probed with either a 1:2000 dilution of an anti-175 
mouse or anti-rabbit IgG horseradish peroxidase conjugate for 1 hour. Bound antibodies 176 
were detected with an ECL detection kit and X-ray film. Quantification of bands was 177 
performed by scanning of blots and quantification using ImageJ. 178 
Surface expression was analysed by flow cytometry as described previously (25). 179 
Briefly, meningococcal cells were harvested from mid-log phase cultures, washed and 180 
resuspended in assay buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 0.05% 181 
Tween-20) containing primary antibody. Samples were incubated for 1 hr at room 182 
temperature, washed thrice and incubated for 1 hour with a 1:100 dilution of an anti-mouse 183 
IgG-fluorescin isocyanate conjugate (Alexa Fluor® 488 Goat Anti-Mouse IgG (H+L), Life 184 
TechnologiesTM). After three washes, cells were resuspended in phosphate-buffered saline 185 
 7
containing 0.05% formalin. Samples were then analysed on a fluorescence-activated cell 186 
sorter and mean fluorescent intensities were determined for each sample. 187 
Expression of the porA gene was assessed by RT-qPCR. Meningococcal strains 188 
were grown to mid-log phase in Mueller-Hinton broth before fixing in Bacteria Protect 189 
Reagent (Qiagen). Total RNA was then extracted using an RNeasy Mini Kit with an 190 
additional RNase-free DNAse step (Qiagen) to remove DNA contamination. Custom 191 
primers and probes used for gene expression assays are listed in Table A1. Reverse-192 
transcription PCR assays (RT-PCR) were completed in MicroAmp® Fast Optical 96-Well 193 
Reaction Plates using TaqMan® RNA-to-CT™ 1-Step Kit (Applied Biosystems). Reactions 194 
were set up in accordance with the Applied Biosystems protocol and analysed on Applied 195 
Biosystems 7500. The house-keeping gene, glucose-6-phosphate 1-dehydrogenase (gdh) 196 
was used as endogenous control gene and H44/76 total RNA as a standard positive 197 
control. Fluorescence was recorded at the end of each extension step according to the 198 
probes present in the reaction, at wavelengths determined by the Applied Biosystems 199 
7500 Fast System Sequence Detection Software.  Relative Quantity (RQ) values were 200 
calculated by the using the 2-ΔΔCT method. The gdh reaction was used as an endogenous 201 
control and all samples were calibrated to the positive control sample. 202 
 203 
Quantification of anti-PorA and anti-CapY antibodies in serum samples. An 204 
immunofluorescence bead-based immunoassay was utilised to quantify variant-specific 205 
PorA antibodies in serum samples. Eight PorA variants (P1.5-1,2-2, P1.19,15, P1.19-1,15-206 
11, P1.5,2, P1.5-2,10, P1.7,16, P1.7-2,4, and P1.21,16) were cloned into an expression 207 
vector enabling production of His-tagged recombinant PorA proteins. A ninth protein 208 
(loopless, P1.-/-) was also produced from which the VR1 and VR2 regions had been 209 
deleted. Proteins were produced as inclusion bodies, purified on a His-tag column in the 210 
presence of urea, re-folded by droplet dilution and finally dialysed into an appropriate 211 
buffer. Polystyrene microspheres labelled with fluorophores (Liquichip Carboxy beads, 212 
BioRad) were coated with nickel-NTA (nitrilotriacetic acid). Each recombinant His-tagged 213 
PorA variant was bound to a spectrally distinct microsphere. 214 
PorA-coupled fluorescent beads were mixed with four dilutions of each serum 215 
sample in Liquichip assay buffer (PBS/0.1% bovine serum albumin/0.05% Triton X-100) in 216 
a 96-well filter plate and incubated for 30 minutes at room temperature on a rocking 217 
platform. Samples were washed three times and then incubated with a 1:25 dilution of a 218 
goat anti-human IgG R-phycoerythrin conjugate (ABD Serotec, Kidlington, UK) in Liquichip 219 
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assay buffer. Finally, samples were washed three times and analysed in a LiquiChip200 220 
Workstation. Raw fluorescence data were converted into arbitrary units (AU) by 221 
comparison to a standard curve generated using serial dilutions of pooled sera from 222 
vaccinees who had been inoculated with either a MenBvac or MenNZB outer membrane 223 
vesicle vaccine (derived from two clinical studies MNB1 and MNB2, respectively). 224 
Separate standard curves were generated for each PorA variant hence comparisons 225 
between AU for each variant are not possible. The quality of each data set was assessed 226 
by statistical evaluation of the parallelism of the lines obtained for the standard curves 227 
using CombiStats version 5 (European Directorate for the Quality of Medicines and 228 
Healthcare, Council of Europe). The AU values for each variant were adjusted for non-229 
specific binding by subtraction of the AU value obtained for the loopless PorA variant, a 230 
value of 0.05 was arbitrarily assigned when binding to this control protein exceeded that to 231 
a particular PorA variant.  232 
The amount of anti-CapY IgG antibodies in each serum samples were measured by 233 
ELISA using purified serogroup Y capsular polysaccharide as a ligand as described in 234 
Gheesling et al. (30). 235 
 236 
Serum bactericidal antibody assays. Serum bactericidal antibody assays were 237 
performed by standard techniques (31) in the Vaccine Evaluation Unit using a ST11 238 
meningococcal strain expressing the serogroup Y antigen (M03-241125, CDC S1975, 239 
Y:P1.5,2:ST11, serotype 2a, fHBP-Oxford 2.2, NadA 2.49, NHBA 29). 240 
 241 
Statistical analyses. Each carrier was examined for significant changes in repeat tract 242 
length between a pair of time points for every gene as follows:- repeat numbers were 243 
determined for six or more colonies for each time point (apart from four time points where 244 
less than six colonies were obtained); repeat numbers were binned into two non-245 
overlapping categories for the two time points; the repeat number of each isolate was 246 
assigned to one of the two categories and placed into a contingency table; a difference 247 
was then deemed significant if a comparison yielded P<0.05 in a Fisher’s exact test. Two-248 
tailed Fisher’s exact tests were performed using GraphPad (graphpad.com/quickcalcs) or 249 
Prism. Chi-squared tests were performed using www.physics.csbsju.edu/stats/. Geometric 250 
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mean concentrations were calculated using Prism. Wilcoxon rank signed tests were 251 
performed in R using the COINS package. 252 
 253 
 254 
RESULTS 255 
Frequent changes occur in the SSRs of eight genes encoding outer membrane 256 
proteins during persistent meningococcal carriage in the upper respiratory tracts of 257 
humans. In order to examine the extent of localised hypermutation occurring during 258 
persistent meningococcal carriage, bacterial samples were obtained from the 259 
nasopharyngeal tissues of individuals colonised with the same meningococcal strain for up 260 
to six months. These samples were from a longitudinal study of meningococcal carriage 261 
performed with a cohort of 190 first year students attending six catered halls at the 262 
University of Nottingham (16). This study was initiated in November 2008, five weeks after 263 
the start of term, and involved four time points (1st, November; 2nd, December; 3rd, 264 
February; 4th, May). We have previously described the identification of persistent carriers 265 
and characterisation of the colonising strains (16). A sub-set of 21 persistent carriers were 266 
selected for further analysis. These carriers were colonised with one of six strains:- 267 
Y:P1.21,16:F3-7:ST1466(cc174, 7 carriers); Y:P1.21,16:F3-7:ST8510(cc174, 1 carrier); 268 
E:P1.5,2:F1-7:ST1383(cc60, 5 carriers); Y:P1.5-1,10-1:F1-3:ST767(cc167, 3 carriers); 269 
Y:P1.5-1,10-1:F4-1:ST1655(cc23, 4 carriers); B:P1.19,15:F5-1:ST5682(cc32, 1 carrier). 270 
Ten of these carriers were persistently colonised for 5-6 months with the same strain, 271 
whilst six exhibited either clearance or replacement of the initial strain by the 4th time point 272 
and the remainder were only examined at early time points. As described previously, 273 
oropharyngeal swabs were spread onto selective agar plates and then streaked to single 274 
colonies prior to overnight growth. Up to 20 single isolates were obtained by re-streaking 275 
single colonies onto non-selective plates for preparation of glycerol stocks and DNA. Thus 276 
all isolates were subject to minimal in vitro passage to reduce the potential for alterations 277 
in PV genotype. Where possible, six or more isolates were analysed as a statistically-278 
representative sample. The similarity of each set of isolates was confirmed by PCR with 279 
primers specific for the relevant capsule, PorA and FetA type (data not shown). 280 
A coherent group of eight genes (porA, fetA, opc, hpuA, hmbR, nadA, mspA and 281 
nalP) encoding phase variable outer membrane proteins with known functional attributes 282 
were chosen for analysis. Most of the other phase-variable meningococcal genes encode 283 
 10
glycosyltransferases, restriction-modification systems or proteins of unknown function (9, 284 
19). The repeat tract of each gene for each strain was amplified and sequenced. Two 285 
genes were not universally present with hmbR only in the cc60 and cc32 strains and nadA 286 
only in the cc174 and cc32 strains (data not shown). The SSR was located in the reading 287 
frame for four genes and exhibited a consistent association between the number of 288 
repeats and whether the reading frame was ‘in-frame’ or out-of-frame’ and hence predicted 289 
to have an ON or OFF expression state, respectively. The predicted ON expression states 290 
for each gene were as follows:- 10G/13G, hpuA; 9G, hmbR; 10C/13C, nalP; and 6C/9C, 291 
mspA. For the other genes, the SSRs were either located upstream of (i.e. the 5’TAAA 292 
tract of nadA) or within the core promoter (polyC tracts in fetA and opc and a polyG tract in 293 
porA; see also Fig. 1A). For these genes, expression state could not be directly predicted 294 
from the sequence data. Flanking sequences and repeat tracts were conserved between 295 
strains (data not shown) with the exception of the cc60 strains, which contained an 296 
interrupted SSR in fetA and a 1 nt deletion in the putative -10 of porA (Fig. A1). A 297 
GeneScan assay was utilised to determine the repeat numbers for each gene in multiple 298 
isolates per time point (Tables A2 and A3). Low levels of variation in tract lengths were 299 
observed within time points (see Fig. 1 and Fig. A2 for examples). Shifts in tract length 300 
between time points were observed for at least one gene in every carrier except V185, 301 
with specific trends being evident for some genes. For example, the fetA SSR in cc174 302 
strains shifted from 9C to 8C or a mix of 10C and 11C variants in 5/8 carriers whilst the 303 
nadA SSR remained at or shifted to 9 or 12 5’TAAA in all 8 of the cc174 carriers. 304 
Comparisons between genes indicated very low levels of alterations in the repeat 305 
tracts of hmbR and mspA whilst all the other genes experienced alterations in 30-40% of 306 
carriers (Fig. 2A). Both fetA and nalP exhibited significantly different frequencies of 307 
switching between the later as opposed to early time points (P<0.05 for comparison of 1st-308 
to-2nd versus 1st-to-4th switching events using a two-tailed Fisher’s exact test), indicative of 309 
a correlation between length of carriage and propensity for PV. A correlation between 310 
mononucleotide repeat tract length and propensity to PV was also observed with no PV in 311 
short tracts (6 or 7 G/C repeats), very low levels in 8G/8C tracts, similar levels in tracts of 9 312 
to 11 repeats and a trend towards increasingly higher levels in longer tracts (Fig. 2B). 313 
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A switching rate per month of carriage was determined for a combination of the 314 
eight phase variable genes with mononucleotide tracts of 9 or more repeats in the 1st/2nd 315 
time point. A significant switch in repeat tract between the 1st/2nd and 4th time points for a 316 
particular gene was calculated as described in the Materials and Methods. The number of 317 
significant switches was divided by the total number of events analysed (i.e. 21/54) and by 318 
the number of months of carriage (i.e. 5 or 6) resulting in an estimate of 0.06 319 
mutations/gene/month of carriage. We conclude that there is a relatively high level of 320 
alterations in the mononucleotide repeat tracts of Nm SSCL during carriage and that gene 321 
type, repeat number and length of host persistence are important determinants of 322 
mutability. 323 
 324 
Persistent meningococcal carriage is associated with accumulation of low 325 
expression states for some phase variable genes. Alterations in the SSRs provide an 326 
indication of mutability but do not test whether there has been a change in phenotype. 327 
Detection of any phenotypic variation associated with these SSCL required analysis of 328 
whether alterations in SSRs mediated gene expression changes. Translational SSR-329 
mediated switching has a predictable correlation between tract length and expression 330 
state. This was confirmed by analysis of SSRs predicted as ‘in-frame’ (i.e. ON) or ‘out-of-331 
frame’ (i.e. OFF) for all four genes (see Fig. 3 and Figs. A3-A7 for hpuA; Oldfield et al. (27) 332 
for mspA and nalP; Tauseef et al. (26), for hmbR). Transcriptional SSR-mediated 333 
switching causes changes in gene expression through modulation of promoter activity and 334 
hence is not readily predicted from repeat tract length. A series of Western blots were 335 
performed for each strain generating associations between tract length and expression 336 
state for porA, fetA, nadA and opc (Fig. 3; Fig. A3-A8; Tables A4-A6). All of the genes 337 
apart from porA exhibited at least three clear expression states ranging from low (>5-fold 338 
reduction) to intermediate to high expression (Table A5). For porA, high/intermediate 339 
levels of expression were detected for multiple tracts whilst the lowest expression state 340 
was only ~5-fold below the highest, larger differences but similar trends were detected in a 341 
quantitative RT-PCR analysis of a sub-set of strains (Table A7). To correlate surface 342 
expression with repeat number, six isolates were investigated by FACs. Variants of a cc32 343 
strain with tracts of 10C or 9C exhibited 9-to-18-fold higher surface expression of FetA 344 
than a variant with an 8C tract whilst similar levels of high expression of porA were 345 
detected in variants of a cc174 with tracts of 11G, 12G or 13G (Fig. A8).  346 
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Expression state data were utilised to classify each SSR/gene combination into an 347 
expression code. Translational-SSR were coded into 0 and 2 for OFF and ON respectively 348 
and transcriptional-SSR into 0, 1 and 2 representing undetectable/low, intermediate and 349 
high expression. Low and intermediate expression were defined as a >5-fold and 1.5-to-5-350 
fold, respectively, reduction relative to high expression as detected by Western blotting for 351 
fetA, opc and nadA or a combination of Western blotting and RT-PCR for porA. A 352 
combined overview of all carriers for all time points detected genic differences in the 353 
proportions of carriage isolates with the highest expression states:- PorA (91%); HpuA 354 
(66%); NalP (65%); FetA (42%); HmbR (24%); MspA (22%); Opc (18%); and NadA (7%) 355 
(Table A6). The largest temporal shift was observed for FetA, which started with 69% of 356 
isolates in the high state and ended with only 11% in this state by the 4th time point (i.e. 357 
after 5-6 months carriage). A significant reduction in FetA expression (P=0.008; Wilcoxon 358 
signed rank test with continuity correction) was observed for a comparison of the mean 359 
initial and final expression states observed across all carriers (Fig. A9). Non-significant 360 
trends were noted for the other genes with NadA and NalP also exhibiting reductions in 361 
expression state (Fig. A9). Expression of NadA was in the lowest state in all of the final 362 
time point samples with the absence of a trend towards reductions in expression being due 363 
to this gene being in the lowest expression state in many of the initial samples. 364 
 365 
Combinatorial reductions in phase variable gene expression occur during persistent 366 
meningococcal carriage. A major advantage of our analysis of multiple phase variable 367 
genes is an ability to examine the combined expression states within an isolate. A 368 
combined code was generated for every isolate using the expression data for the 6 or 7 369 
phase variable genes present and analysed in each clonal group. These codes contain 370 
both genotypic and phenotypic information and hence are referred to as ‘phasotypes’. 371 
Seven genes - three with two states and four with three states - could generate 648 372 
phasotypes. A total of 25 phasotypes was observed for the combined data for the 140 373 
isolates of cc174, indicating a limited exploration of the potential expression states (Table 374 
A8).  375 
Each phasotype contains information on the combined expression states of the 376 
genes, which is a simple sum of the individual gene states (i.e. 2-2-2-2-2-2-2 has score 14, 377 
2-2-2-2-2-2-0 is 12, etc). The phasotypes were grouped by ‘expression score’ and the 378 
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patterns of change between time points were examined for each carrier (Fig. 4A-C). The 379 
mean phasotype score was also calculated for each time point of every carrier (data not 380 
shown) and the change in this score plotted against months of carriage (Fig. 4D). The 381 
cc167 and cc23 strains were combined as they have identical PorA sub-types (P1.5-1,10-382 
1) and gene combinations (i.e. absence of nadA and hmbR). Only one carrier exhibited no 383 
change in expression score (V185; persistent carrier of a serogroup E, cc60 strain) whilst 384 
varying patterns of changes were observed in other carriers. A reduction in phasotype 385 
score was observed in 11 of the 21 carriers between the initial and final time point of 386 
observed carriage but was variable between strains with a shift towards lower expression 387 
phasotypes in 6/8, 4/7, 0/5 and 1/1 of the cc174, cc167/cc23, cc60 and cc32 strains, 388 
respectively. A significant change towards a lower mean phasotype score was detected for 389 
the cc174 carriers (P = 0.03 in a Wilcoxon rank test with continuity correction) but not for 390 
the cc167/cc23 or cc60 strains. The absence of a shift towards lower expression scores in 391 
the cc60 strains could be due to only one of these carriers exhibiting more than three 392 
months observed carriage and three of the genes having short repeat tracts (fetA, 6G; 393 
nalP, 7C; mspA, 8C). Overall, persistent carriage is associated with a shift towards lower 394 
combined phasotype scores but exhibits a strain bias. 395 
The effect of persistence length on the reduction in phasotype score was examined 396 
for all 21 carriers. A trend was observed for reductions in phasotype score as a function of 397 
persistent carriage such that 44% (8/18), 50% (8/16) and 70% (7/10) of carriers exhibited 398 
reduced scores relative to the initial time point after 1, 2-3 or 5-6 months carriage. Analysis 399 
of the phasotype scores for isolates provided further evidence of the effect of prolonged 400 
carriage (Table 1). Thus for the cc174 isolates, there was a significant shift from 85% with 401 
a score of ≥7 in the initial time point to 100% with ≤6 after 5-6 months carriage (P>0.001 in 402 
a Chi-squared test). Similarly, there was a reduction in expression score from 65% with ≥7 403 
to 62% with ≤6 for the cc167/cc23 isolates (P=0.002). Conversely, the cc60 strains 404 
exhibited a significant trend towards rising phasotype scores (P=0.002) however, as 405 
discussed above, there was a lack of data for more than three months carriage with this 406 
clonal complex. Thus, prolonged carriage is associated with reductions in phasotype score 407 
and the accumulation of phasotypes with lower expression states. 408 
 409 
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Variant-specific PorA antibodies can be detected using a multiplex microserology 410 
assay in sera from persistent meningococcal carriers. In order to understand why 411 
switches in the phase-variable genes are occurring it is important to characterise the 412 
selective pressures acting on the products of these genes. Adaptive immune responses 413 
exert a strong selective pressure on the surface antigens of meningococci with a 414 
significant potential impact on PV expression status. The phase variable PorA protein is a 415 
major component of the outer membrane and contains two variable regions, VR1 and 416 
VR2, which are the main targets for bactericidal meningococcal antibodies and are also 417 
utilised for strain typing with VR specific mAbs (32). We tested for the presence of VR 418 
region specific PorA antibodies in serum samples collected concomitantly with 419 
nasopharyngeal swabs from the 21 persistent carriers. These sera were complemented 420 
with additional sera from the same carriage study (16), this included a set of sera from 421 
persistent non-carriers as controls and sera from volunteers exhibiting acquisition of 422 
carriage as a test of whether gain-of-carriage was associated with induction of 423 
meningococcal specific antibodies. 424 
The levels of PorA-specific IgG antibodies were analysed using a multiplex 425 
fluorescent-microsphere protocol and a Liquichip workstation (Qiagen). A single 426 
combination of seven PorA variants was utilised for the majority of the assays, which 427 
included PorA variants with VRs similar/identical to those present in the carriage isolates 428 
and a modified PorA, lacking VR1 and VR2, used as a control for background reactivity 429 
(Patel, Chan and Feavers, unpublished data). Antibody levels were measured in arbitrary 430 
units (AU) relative to pooled meningococcal vaccinee sera and hence quantitative 431 
comparisons of reactivity between variants was not possible. 432 
The specificity and reproducibility of the multiplex PorA assay was previously 433 
validated utilising variant-specific PorA monoclonal antibodies but has not been 434 
extensively tested with sera from carriers of known PorA variant type (Patel, Chan, 435 
Findlow, Borrow, Trotter and Feavers, unpublished data). We, therefore, analysed the 436 
results for evidence of specificity and utility in detection of variant specific antibodies 437 
(Table A9, Table A10 and data not shown). Importantly, general reactivity to all PorA 438 
variants was noted as being very low, and probably due to non-specific background, in 439 
persistent non-carriers (Table 2; Fig. 5). High levels of monospecific activity were detected 440 
in at least one of the time points for five carriers (V51, V54, V64, V69 and V185) against 441 
the PorA variant protein containing one or both VRs matching the carriage isolate. Sera 442 
from other carriers exhibited a high level of reactivity mainly to the homologous PorA 443 
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variant whilst three carriers (V59, V88 and V124) had a pan-response against all variants 444 
and three (V93, V138 and V176) had non-carrier levels of reactivity. Thus some carriers 445 
exhibit monospecific responses whilst others elicit varying degrees of cross-reactivity, 446 
which could be due to cross-reactive epitopes, recent carriage of other strains or a 447 
‘bystander’ induction of responses to all previously-encountered PorA variants. The 448 
specificity of these responses was confirmed for a selection of samples by using VR 449 
specific mAbs to block binding of antibodies to one of the VRs (Table A10). Both VR1 and 450 
VR2 specific mAb antibodies reduced binding of serum antibodies but VR2 antibodies 451 
were generally more effective at blocking reactivity. Overall, the multiplex assay exhibited 452 
utility for detection of variant-specific IgG PorA antibodies in sera from meningococcal 453 
carriers. 454 
 455 
Persistent meningococcal carriage is associated high levels of adaptive immune 456 
responses against surface determinants. The above studies indicated that variant-457 
specific PorA antibodies could be readily detected in the sera of these carriers. However, 458 
as variability in the antigenic regions of PorA prevented direct comparisons between 459 
strains, antibody responses against the serogroup Y (MenY) capsular antigen were also 460 
investigated to facilitate comparisons between volunteers and due to the high prevalence 461 
of MenY strains among our persistent carrier samples. Immune responses to the 462 
serogroup Y capsular antigen were assessed by a CapY-IgG specific ELISA (i.e. with 463 
purified capsular polysaccharide). The sera were also tested for bactericidal antibodies 464 
using an ST-11 strain expressing a serogroup Y capsule and a P1.5,2 PorA variant. As the 465 
PorA protein was mismatched in either both VRs (cc174) or VR2 (cc167/cc23), this assay 466 
will mainly detect bactericidal IgM and IgG anti-CapY antibodies. The expression states 467 
and/or sequence variation, as compared to test strains, in the other phase-variable genes 468 
were however unknown and may make a minor contribution to bactericidal titre. 469 
Sera from carriers subject to different types of carriage (acquisition, clearance and 470 
clonal replacement, and persistent) were analysed to determine the levels and temporal 471 
behaviour of antibody responses (Table A9; Fig. 5). As observed for PorA, most of the 472 
non-carriers had low levels of CapY IgG antibodies and low SBA titres apart from three 473 
who had with either high CapY IgG (V135 and V150) or high SBA (V97) titres, which could 474 
be due to carriage of homologous meningococcal strains prior to enrolment in the study or 475 
vaccination with a CapY-conjugate vaccine. Acquisition of carriage was associated with a 476 
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significant rise in variant-specific PorA antibodies and SBA titre and a non-significant 477 
increase in anti-CapY IgG. Antibody levels and SBA titres increased as a function of time 478 
post-colonisation. Replacement or clearance of the initial strain was associated with high 479 
PorA and CapY IgG antibody concentrations and high SBA titres similar to persistent 480 
carriers with no significant overall decrease following loss of carriage, suggesting 481 
persistence of antibodies in the absence of on-going stimulation. Significantly higher levels 482 
of reactivity were detected in sera from persistent carriers as compared to non-carriers to 483 
the homologous PorA type and CapY at all time points (Fig. 5A and 5B). Similarly, SBA 484 
titres were higher in persistent carriers than non-carriers although a small but significant 485 
drop in SBA titre was found in the fourth time point possibly due to waning of a specific 486 
IgM response (Fig. 5C). A major increase between the November (i.e. first) and later time 487 
points in both anti-PorA and anti-CapY antibodies was observed in two carriers, V88 and 488 
V43, whilst two others exhibited increases in PorA IgG (V64) or CapY IgG (V51). These 489 
rises were indicative of recent colonisation and commensurate with the timing of sample 490 
collection, which was performed near to the start of term when high levels of spread of 491 
meningococcal strains is anticipated among this typical group of university students. 492 
Relative amounts of antibodies were assessed for the 21 carriers subject to PV 493 
analysis in groups comparable to those utilised for the phasotype scores (Table 2). The 494 
cc174 and cc167/cc23 strains exhibited higher concentrations of CapY IgG and SBA titres 495 
than non-carriers at all time points (P<0.05 with an unpaired T test) apart from a non-496 
significant difference in CapY IgG at the 1st time point in cc174 carriers probably due to 497 
recent colonisation in three of these carriers (V43, V51 and V88) and hence insufficient 498 
time for elicitation of antibodies. The levels of variant-specific PorA antibodies were 499 
significantly higher in the cc167/23 and cc60 carriers than non-carriers (P<0.05). Six of the 500 
cc174 carriers had 10-fold higher levels of P1.21,16 specific PorA antibodies levels than 501 
non carriers at two or more time points but specific antibodies weren’t detectable in two 502 
(V59 and V138) carriers. 503 
In nine of the eleven carriers exhibiting a drop in average phasotype score, high 504 
variant-specific PorA antibodies, CapY responses and SBA titres were detected at multiple 505 
time points during persistence of the meningococcal clone. Of the others, one (V88) 506 
exhibited a late rise in PorA levels at the third time point, correlating with a major reduction 507 
in phasotype score, whilst in V54 the CapY IgG and SBA response were weak but the 508 
PorA specific responses were very high. The exception was for carrier V176 wherein no 509 
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PorA antibodies could be detected. Collectively, we detected high levels of surface-antigen 510 
specific and bactericidal antibodies in the majority of persistent carriers in which phase 511 
variable reductions in OMP expression were observed. 512 
 513 
DISCUSSION 514 
Contingency loci are present in many pathogenic and commensal bacteria and are thought 515 
to generate high levels of genetic variation enabling adaptation to fluctuations in the 516 
stringent selective pressures exerted by the host milieu. A significant gap in our 517 
understanding of contingency loci is the extent of their contributions to natural infections 518 
whether asymptomatic or disease-associated. This study has determined the frequencies 519 
and patterns of SSR-mediated PV occurring during asymptomatic, persistent carriage of 520 
Nm, a pathogen/commensal with multiple contingency loci, in the upper respiratory tract of 521 
humans - their only hosts - and detected trends towards lower expression states for 522 
specific and combinations of phase variable surface proteins (herein termed ‘phasotypes’). 523 
Our report highlights the importance of examining bacterial isolates from natural 524 
environments and implies a role for PV in facilitating persistent carriage of a bacterial 525 
pathogen. 526 
By measuring variation in eight contingency loci, we estimate that the SSR-527 
mediated PV rate for polyG/C tracts of 9 or more repeats is 0.06 mutations/gene/month of 528 
carriage for Nm in the upper respiratory tract of humans. In contrast, genetic variation in 529 
the VRs of PorA was only detected in one of these 21 carriers and no variation was 530 
detected in the FetA VRs (16 and data not shown) indicating an antigenic variation rate of 531 
0.006/gene/month of carriage (1 mutation in 172 months of carriage). Thus changes in the 532 
structure of an antigen by point mutation or recombination following lateral gene transfer 533 
are infrequent as compared to phase-variable alterations in expression mediated by 534 
mutations in SSR tracts. There are 30-40 phase variable genes in each Nm strain most of 535 
which modify OMPs or the structures of surface determinants. Thus localised 536 
hypermutation is the major source of genetic variability occurring during asymptomatic 537 
carriage of a meningococcal clone within an individual person. 538 
  Temporal fluctuations in the selective pressures acting on the different expression 539 
states of phase-variable loci is likely to be the major force driving any temporal patterns in 540 
alterations to the SSR tracts. Thus selection for the ON state may be balanced and 541 
exceeded by selection for the OFF state during long-term host persistence of a 542 
meningococcal strain resulting in an observation of ON-to-OFF switching. A key finding 543 
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from our phenotypic analysis of SSCL was for switches to lower expression states of 544 
specific OMPs – namely NadA, FetA and NalP - during persistent carriage. The other 545 
phase variable OMPs showed either variability in their expression states or, in the case of 546 
PorA, a continuous high expression state. It should be noted that all our results pertain to 547 
events on the mucosal surface as sampling of carriers was by swabbing of epithelial 548 
surfaces. One implication of the observed accumulation of OFF variants as a function of 549 
persistent carriage is that once colonisation has been established within an individual, 550 
selection for high/ON expression states of phase variable OMPs is reduced and selection 551 
for OFF expression states can drive phase variable loci into minimal expression states. 552 
The nadA gene was found in a low expression state in all isolates except a few from early 553 
time points (Fig. 1A; Table A2). As this gene encodes an adhesin (33,34), our results 554 
suggest that NadA is only required for initial colonisation and is rapidly subject to selection 555 
for loss of expression as Nm persists in a host. Similar requirements during colonisation 556 
may be ascribed to Opc and MspA, which encode known and putative adhesins (35,36) 557 
and were also found mainly in low expression states (52% for Opc; 78% for MspA; Table 558 
A6). The FetA OMP showed a significant trend towards lower expression states as a 559 
function of persistence (Fig. A10) and a high prevalence of ON variants during early time 560 
points (Table A6). The prevalence of high-expressing variants of FetA was partially due to 561 
clonal expansion of the cc174 strains in one hall of residence (16). However the 562 
siderophore-binding iron-uptake attributes of FetA (37) may mean that siderophores are a 563 
potent source of iron during initial colonization by Nm but are replaced by other sources 564 
(transferrin and haemoglobin) as bacterial numbers increase and perturb the normal 565 
mucosal surface. Finally, NalP showed a trend towards an OFF expression state possibly 566 
connected with a growing requirement for establishment of a biofilm, which NalP 567 
antagonizes by cleavage of other surface meningococcal proteins (38,39). 568 
  The above discussion indicates how selection for the functions of phase variable 569 
OMPs could result in an elevated prevalence of high/ON expression at specific times 570 
during persistent carriage, but, apart from NalP, has not elaborated on how selection for 571 
low/OFF expression states is exerted. A novel approach pioneered for C. jejuni isolates 572 
(40) and utilised in this study was to examine isolates for alterations in the combined 573 
expression states of multiple phase-variable loci. The term ‘phasotypes’ has been adopted 574 
herein (see also 41) to convey the idea that these types are based on conversion of non-575 
arbitrary genotypic information (i.e. SSR repeat number) into a potential phenotypic state. 576 
Phasotype does not indicate an actual in vivo phenotypic state as expression of some of 577 
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these phase-variable genes may be controlled by external signals (i.e. fetA is iron-578 
regulated). Nevertheless changes in the ‘phasotype’ are indicative of how the bacterial 579 
cells are responding to selective forces. We note that the ‘phasotype’ system is portable 580 
and could be utilised by other laboratories for comparisons of the expression states of 581 
phase-variable genes. 582 
   A novel finding from our analysis of phasotypes is for an overall decrease in surface 583 
expression of multiple OMPs during persistent mucosal carriage. This observation implies 584 
that selection is acting on the combination of genes present on the Nm surface. One 585 
explanation for this finding is that meningococcal cells expressing lower amounts of OMPs 586 
have a growth advantage and replace high OMP expressers. This selective pressure is, 587 
however, probably very weak and easily counteracted by any selection for expression of a 588 
gene. A second explanation is that adaptive immune responses against surface OMPs 589 
select for antigenic variation and reduced expression states. 590 
  Multiple studies have shown that Nm carriage elicits serum IgG and bactericidal 591 
antibodies against a range of OMPs, including PorA, Opc, PilE and NadA, and other 592 
surface molecules such as the capsule and lipopolysaccharide (13,42). Mucosal IgA 593 
responses to whole Nm cells and to PorA have also been detected (43,44). We 594 
demonstrated the presence of high levels of IgG antibodies specific for the homologous 595 
PorA variant in the majority of persistent carriers and high levels of anti-CapY specific IgG 596 
antibodies (Table 2; Fig. 5). Furthermore we show that these high levels persist through 597 
six months continuous carriage, that specific antibodies are rapidly elicited upon 598 
acquisition of carriage and that there is also a strong serum bactericidal activity response. 599 
Whilst we have yet to confirm whether antibody responses are elicited against all nine 600 
OMPs, our results suggest that a robust anti-OMP response is generated as observed in 601 
other Nm carriers. As selection of low-expression PorA phase variants has been observed 602 
in vitro (25), the absence of an effect of the specific antibodies on PorA expression levels 603 
is a contraindication for a role of the adaptive immune response. However, adaptive 604 
immune responses may exert only a weak effect that could be counteracted by a stronger 605 
selection for expression of this OMP. Variability in the strength of selection for the high/ON 606 
states of other OMPs may permit weak immune selection to drive these proteins into lower 607 
expression states. Variability in the patterns of switching between OMPs may also 608 
emanate from another source. Reduction in the combination of surface expressed OMPs 609 
implies an effect on the complexity of the bacterial surface rather than the amount of each 610 
protein. This could be due to the observed synergistic effects of bactericidal antibodies 611 
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against multiple minor OMPs (45) or cross-linking and neutralization of bacterial cells by a 612 
polyclonal secretory IgA response (46), resulting in variability in which OMP is down-613 
regulated between isolates and carriers. Overall, our findings are supportive of the 614 
hypothesis that prolonged exposure to antibody-mediated selection drives Nm cells 615 
towards reduced expression states for phase variable OMPs during persistent carriage in 616 
their natural hosts. Thus PV may facilitate host persistence by mediating escape of 617 
adaptive immune responses whilst simultaneously rendering the resident Nm strain more 618 
sensitive to clearance by innate immune effectors or to competition and replacement by an 619 
antigenically-divergent Nm strain. 620 
  The reductions in expression of OMPs have potential implications for 621 
meningococcal protein vaccines. Two of these proteins, NadA and PorA, are present 622 
within the recently-licensed Bexsero® vaccine whilst NalP modifies NHBA another 623 
component of this vaccine (47,48). The FetA protein has also been proposed as a 624 
potential vaccine candidate (49). The accumulation of low expression variants of NadA 625 
and FetA indicates that vaccines including these antigens would not prevent persistent 626 
carriage but would be most likely to act during the initial stages of host colonization. 627 
Testing for herd immunity by meningococcal vaccines will therefore require a focus on 628 
prevention of acquisition of carriage in naïve individuals and a careful design of vaccine 629 
trials to monitor the relative times of strain acquisition and vaccine-induced antibody 630 
responses. 631 
  This study has defined the frequency and patterns of alterations in SSCL encoding 632 
eight OMPs during persistent Nm carriage. Our results indicate persistent carriage of Nm 633 
populations is associated with reductions in expression of single and combinations of 634 
SSCLs with evidence for adaptive immune responses being one of the major selective 635 
pressures driving the population into this state. Comparisons of the phasotypes of these 636 
carriage isolates with disease isolates of similar strain types can now be performed to 637 
determine whether particular phasotypes are required for meningococci to cause disease 638 
and if the lack of disease associated with long-term carriage of meningococci is due simply 639 
to the specific immune responses or is also prevented by the accumulation of non-invasive 640 
phasotypes. 641 
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Figure 1. Changes in repeat tract length of five genes during persistent carriage of cc174 830 
strains. Multiple meningococcal isolates of the same strain were collected from eight 831 
volunteers (labelled as V in the figure) persistently colonised with a cc174 serogroup Y 832 
strain either ST1466 (V51, V52, V58, V59, V88, V138) or ST8510 (V54; V43 exhibited 833 
replacement of ST8510 with ST1466 between the first and second time points). Up to six 834 
isolates per time point were analysed for up to four time points (1st-4th which were 835 
separated by 1, 2, or 3 months respectively) for the number of simple sequence repeats in 836 
five phase variable genes as follows:- panel (A), fetA (polyG tract, open circles), nadA 837 
(tetranucleotide 5’TAAA tract, open triangles), porA (polyG tract, filled triangles); panel (B), 838 
hpuA (poly G tract, filled diamonds) and opc (polyG tract, open squares). 839 
 840 
Figure 2. Effect of persistent carriage on changes in the repeat tracts of phase variable 841 
meningococcal genes. Each gene was examined for significant changes in repeat tract 842 
length between a pair of time points for carriers persistently colonised with the same 843 
meningococcal strain and plotted as the percentage of carriers with no significant changes. 844 
The total number of carrier samples examined for each of the four pairs of time points 845 
were:- fetA (18, 16, 7, 10); porA (18, 16, 7, 10); opc (18, 16, 7, 10); nadA (9, 8, 4, 5); hpuA 846 
(18, 16, 7, 10); hmbR (5, 3, 1, 2); nalP (18, 16, 7, 10); mspA (18, 16, 7, 10). Time points 847 
were:- 1st to 2nd (1 month), black bars; 2nd to 3rd, (2 months), dark grey bars; 3rd to 4th, 848 
(3 months), light grey bars; 1st-4th or 2nd-4th (5 or 6 months respectively), white bars. 849 
Panel (A) shows changes per gene. Panel (B) shows changes as a function of the repeat 850 
tract length relative to the tract length in the initial time point of each pair. 851 
 852 
Figure 3. Comparison of protein expression levels for cc174 phase variants with different 853 
tract lengths. Whole cells lysates were prepared from meningococcal cells grown to mid-854 
log phase with (lanes 1-7) or without (lanes 8-14) induction of iron-repressed genes. 855 
Western blots were probed with 1:1,000 or 1:2,000 dilutions of primary antibodies/antisera 856 
(see Table 1A) followed by an appropiate secondary antibody. Note that the an anti-F1-3 857 
FetA variant mouse polyclonal and an anti-meningococcal serotype P1.16 mouse mAb 858 
were used to detect FetA and PorA, respectively, whereas the other antisera recognise a 859 
wide range of antigenic types of the relevant protein. Repeat numbers are indicated as 860 
either the number of ‘G’s in a polyG tract or, for nadA, the number of 5’TAAA repeats. 861 
Lanes 1 and 8, N54.1; lanes 2 and 9, N343.5; lanes 3 and 10, N369.1; lanes 4 and 11, 862 
N352.3; lanes 5 and 12, N288.5; lanes 6 and 13, N343.2; lanes 7 and 14, N438.3. These 863 
 26
isolates were from two different cc174 ST-types – ST8510 (N54, N343) and ST1466 864 
(N288, N352, N369, N438). 865 
 866 
Figure 4. Longitudinal alterations in the multiplex phase variation expression states during 867 
persistent carriage of meningococcal strains. The expression states of phase variable 868 
genes were determined from a combination of repeat number and direct assessments of 869 
expression state by Western blotting. The expression states of phase variable loci were 870 
coded as 0 (OFF/low), 1 (intermediate) and 2 (ON/high) - see text. The combined pattern 871 
of expression states (i.e. phasotypes) for six or seven genes (as indicated in each panel) 872 
were determined for up to six isolates per time point. A total score was assigned to each 873 
phasotype by combining the expression scores of individual genes (i.e. seven genes in 874 
their maximum expression state scores 14) and then phasotypes with similar scores were 875 
colour-coded and plotted in panels A-C:- red (10-14); orange (8-9), magenta (7); yellow 876 
(6); green (4-5); and blue (0-3). A mean score for each time point of each volunteer was 877 
calculated from these total phasotype scores. Panel (A), eight cc174 carriers and one cc32 878 
carrier (V176); panel (B), five cc60 carriers; panel (C), three cc167 and four cc23 carriers. 879 
Panel (D), graphs for three groups of strains, cc174, cc60 and cc167/cc23, showing the 880 
change in mean score relative to the initial time point when carriage was first detected. 881 
 882 
Figure 5. Antigen-specific immune responses in serum samples from meningococcal 883 
carriers. Volunteers were grouped into four categories according to the type of 884 
meningococcal carriage detected by nasopharyngeal swabbing:- Persistent Carriers, same 885 
strains detected at all time points; Acquisition, progression from absence to presence of 886 
carriage with time points separated into pre-colonisation (Pre) and less than or more than 887 
three months after colonisation (i.e. Post(<3) and Post(>3) respectively); 888 
Replacement/Clearance, initial strain either replaced by antigenically-different strain or not 889 
detected in the 4th time point; Non-carriers, no meningococcal carriage detected at any 890 
time point. One to four sera were analysed for each volunteer. Panel A, anti-PorA IgG 891 
antibodies detected by a multiplex fluoresecence-bead assay (AU, arbitrary units). Panel 892 
B, anti-CapY IgG antibodies detected by ELISA against purified capsular antigen. Panel C, 893 
serum bactericidal activity against an ST-11 meningococcal strain expressing a serogroup 894 
Y capsular antigen. Values represent the dilution providing 50% killing. 895 
 896 
897 
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Table 1. Longitudinal changes in expression states of phase variable meningococcal genes 898 
Phasotype Score1 Number of Isolates Per Observed Months of Carriage (%) Initial 1 month 2-3 months 5-6 months 
cc174 (FetA-Opc-NadA-HpuA-PorA-NalP-MspA) 
10 5 (10%) 2 (5%) 0 0 
9 4 (8%) 0 0 0 
8 24 (50%) 22 (55%) 14 (38%) 0 
7 8 (17%) 1 (3%) 7 (19%) 0 
6 7 (15%) 15 (38%) 7 (19%) 15 (63%) 
5 0 0 1 (3%) 2 (8%) 
0-4 0 0 8 (21%) 7 (29%) 
Total 48 40 37 24 
cc60 (FetA-Opc-HmbR-HpuA-PorA-NalP-MspA) 
8 6 (20%) 17 (57%) 7 (58%) 6 (100%) 
7 5 (17%) 5 (17%) 1 (8%) 0 
6 11 (37%) 8 (27%) 4 (33%) 0 
5 8 (27%) 0 0 0 
Total 30 30 12 6 
cc167/cc23 (FetA-Opc-Hpua-PorA-NalP-MspA) 
10-12 8 (21%) 5 (21%) 5 (14%) 0 
9 6 (16%) 8 (33%) 11 (31%) 2 (8%) 
8 2 (5%) 5 (21%) 8 (22%) 4 (17%) 
7 5 (13%) 0 0 3 (13%) 
6 5 (13%) 0 1 (3%) 2 (8%) 
5 12 (32%) 6 (25%) 8 (22%) 8 (33%) 
0-4 0 0 3 (8%) 5 (21%) 
Total 38 24 36 24 
cc32 (FetA-Opc-NadA-HpuA-PorA-NalP-MspA) 
10-12 6 (100%) 5 (83%) 4(67%) 3 (50%) 
9 0 0 2 (33%) 3 (50%) 
6 0 1 (17%) 0 0 
Total 6 6 6 6 
1Genotype score was determined from a combination of the expression states for 6-7 genes as 899 
outlined in brackets for each clonal complex and Table A8. 900 
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Table 2. Levels of anti-PorA, anti-CapY and bactericidal antibodies in serum of meningococcal 902 
carriers 903 
Antigen/Antibody 
type or activity1 
Geometric Mean Antibody Concentration or Titre at Each Time Point 
(range, number of samples) 
1st (Nov) 2nd (Dec) 3rd (March) 4th (May) 
cc174 (Y:P1.21,16) 
P1.21,16/IgG 1.4 (0.05-40.5; 8) 1.5 (0.05-40.7; 8) 3.4 (0.05-76.1; 8) 1.7 (0.05-25.07; 7)
CapY/IgG 1.8 (0.3-20.5; 5) ND2 3.8 (0.4-17.1; 4) 4.6 (0.6-27.5; 7) 
CapY/SBA 1077 (3-8192; 8) 6889 (4096-16384; 4) 2656 (128-8192; 8) 939 (32-4096; 8) 
cc60 (E:P1.5,2) 
P1.5,2/IgG 1.5 (0.2-4.1; 3) 2.7 (0.5-7.8; 3) 1.5 (0.4-8.0; 3) ND 
cc167/cc23 (Y:P1.5-1,10-1)
P1.5-2,10/IgG 1.4 (0.5-6.8; 6) 1.2 (0.3-2.7; 7) 3.2 (0.3-17.2; 6) 3.9 (2.8-8.0; 6) 
CapY/IgG 15.2 (8.6-38.5; 4) 9.2 (7.5-11.2; 2) 20.5 (6.4-29.8; 4) 14.9 (4.4-67.3) 
CapY/SBA 1465 (3-16384; 5) 
2353 (128-16384; 
5)
4598 (2048-16384; 
6)
1783 (1024-8192; 
5)
cc32 (B:P1.19,15) 
P1.19,15 0.1 (NR; 1) 0.1 (NR; 1) 0.2 (NR; 1) 0.3 (NR; 1) 
Non-carriers 
PorA/IgG 0.2 (0.1-0.5; 8) 0.1 (0.1-0.6; 6) 0.2 (0.1-0.6; 5) 0.4 (0.2-0.9; 2) 
CapY/IgG 0.2 (0.1-0.3; 5) ND 0.2 (0.1-0.2; 4) 
CapY/SBA 5 (3-128; 8) 7 (3-256; 5) 3 (3-8; 3) 9 (3-512; 8)
1Antibody concentrations:- PorA (P1) variants, arbitrary units; serogroup Y capsular antigen 904 
(CapY), ug/ml; serum bactericidal activity (SBA) for an ST-11/Y strain, highest dilution resulting in 905 
≥50% killing; 2ND, no data; NR, not relevant. 906 





